Abstract

7507Background: Treatment strategies to improve outcomes in HR FL are needed. E2408 tested whether bortezomib (V) improves the CR rate when added to standard BR induction in untreated HR FL and whe...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group
Philip Dy ... Timothy E O'Brien
Blood | VOL. 130
Philip Dy, et. al.Philip Dy ... Timothy E O'Brien
25 Jun 2021
Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma
Ashley Morrison ... Alex V Mejia Garcia
Blood | VOL. 136
Ashley Morrison, et. al.Ashley Morrison ... Alex V Mejia Garcia
05 Nov 2020
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study
Lynne I Wagner ... Giselle K Perez
Blood | VOL. 136
Lynne I Wagner, et. al.Lynne I Wagner ... Giselle K Perez
05 Nov 2020
Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa
Franck Morschhauser ... Marc André
Blood | VOL. 142
Franck Morschhauser, et. al.Franck Morschhauser ... Marc André
28 Nov 2023
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers